Taegyun Yun
Research Subjects
Research Interests
Taegyun Yun has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Jin-Young Jang
Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
1 shared publication - Junghyun Namkung
Immunodiagnostics R&D Team, IVD Business Unit, New Business Division, SK telecom Co., Seongnam, Korea
1 shared publication - Mee Joo Kang
Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Republic of Korea
1 shared publication - Min-Seok Kwon
Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, Korea
1 shared publication - Sangjo Han
Immunodiagnostics R&D Team, IVD Business Unit, New Business Division, SK telecom Co., Seongnam, Korea
1 shared publication - Seungyeoun Lee
Department of Mathematics and Statistics, Sejong University, Seoul 05006, Korea
1 shared publication
Latest Publications
- Open Access
- 17 August 2015
- Published by Springer Nature in BMC Genomics
- Vol. 16 (S9) , S4
Integrative analysis of multi-omics data for identifying multi-markers for diagnosing pancreatic cancer
MicroRNA (miRNA) expression plays an influential role in cancer classification and malignancy, and miRNAs are feasible as alternative diagnostic markers for pancreatic cancer, a highly aggressive neoplasm with silent early symptoms, high metastatic potential, and resistance to conventional therapies. In this study, we evaluated the benefits of multi-omics data analysis by integrating miRNA and mRNA expression data in pancreatic cancer. Using support vector machine (SVM) modelling and leave-one-out cross validation (LOOCV), we evaluated the diagnostic performance of single- or multi-markers based on miRNA and mRNA expression profiles from 104 PDAC tissues and 17 benign pancreatic tissues. For selecting even more reliable and robust markers, we performed validation by independent datasets from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) data depositories. For validation, miRNA activity was estimated by miRNA-target gene interaction and mRNA expression datasets in pancreatic cancer. Using a comprehensive identification approach, we successfully identified 705 multi-markers having powerful diagnostic performance for PDAC. In addition, these marker candidates annotated with cancer pathways using gene ontology analysis. Our prediction models have strong potential for the diagnosis of pancreatic cancer.
- 17 August 2015
- Published by Springer Nature in BMC Genomics
- Vol. 16 (S9) , S4
Open AccessIntegrative analysis of multi-omics data for identifying multi-markers for diagnosing pancreatic cancer
MicroRNA (miRNA) expression plays an influential role in cancer classification and malignancy, and miRNAs are feasible as alternative diagnostic markers for pancreatic cancer, a highly aggressive neoplasm with silent early symptoms, high metastatic potential, and resistance to conventional therapies. In this study, we evaluated the benefits of multi-omics data analysis by integrating miRNA and mRNA expression data in pancreatic cancer. Using support vector machine (SVM) modelling and leave-one-out cross validation (LOOCV), we evaluated the diagnostic performance of single- or multi-markers based on miRNA and mRNA expression profiles from 104 PDAC tissues and 17 benign pancreatic tissues. For selecting even more reliable and robust markers, we performed validation by independent datasets from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) data depositories. For validation, miRNA activity was estimated by miRNA-target gene interaction and mRNA expression datasets in pancreatic cancer. Using a comprehensive identification approach, we successfully identified 705 multi-markers having powerful diagnostic performance for PDAC. In addition, these marker candidates annotated with cancer pathways using gene ontology analysis. Our prediction models have strong potential for the diagnosis of pancreatic cancer.